Drug Interactions between allopurinol / lesinurad and medroxyprogesterone
This report displays the potential drug interactions for the following 2 drugs:
- allopurinol/lesinurad
- medroxyprogesterone
Interactions between your drugs
medroxyPROGESTERone lesinurad
Applies to: medroxyprogesterone and allopurinol / lesinurad
ADDITIONAL CONTRACEPTION RECOMMENDED: Coadministration with lesinurad may decrease the plasma concentrations of contraceptive hormones and reduce their effectiveness. The interaction has not been evaluated in pharmacokinetic studies. However, lesinurad is a weak inducer of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of contraceptive hormones. Lesinurad has been shown to induce the metabolism of other CYP450 3A4 substrates in interaction studies.
MANAGEMENT: Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable when used with lesinurad. Female patients of reproductive potential receiving hormonal contraceptives should practice additional methods of contraception during treatment with lesinurad.
References (1)
- (2015) "Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals
Drug and food interactions
allopurinol food
Applies to: allopurinol / lesinurad
ADJUST DOSING INTERVAL: The tolerability of allopurinol may be improved by giving it after a meal. Additionally, when the dose is greater than 300 mg, dividing the total daily dose into smaller doses administered more often may be appropriate to help minimize gastrointestinal irritation.
MONITOR: Concomitant use of allopurinol with central nervous system (CNS) depressants, including alcohol, may potentiate adverse effects such as somnolence and sedation.
MANAGEMENT: To improve tolerability, some manufacturers suggest administering allopurinol after a meal. Additionally, if the daily dose is greater than 300 mg, administering allopurinol in divided doses may help reduce gastrointestinal intolerance. Patients should also be counseled to avoid or limit consumption of alcohol and to avoid activities requiring mental alertness such as driving or operating hazardous machinery until they know how the medication affects them.
References (4)
- (2024) "Product Information. Allopurinol (Sandoz) (allopurinol)." Sandoz Pty Ltd
- (2021) "Product Information. Zyloric (allopurinol)." Aspen Pharma Trading Ltd
- (2021) "Product Information. Zyloprim (allopurinol)." AA Pharma Inc, 248178
- (2024) "Product Information. Allopurinol (allopurinol)." Actavis U.S. (Purepac Pharmaceutical Company)
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.